MUTUAL PHARMACEUTICAL COMPANY, INC. Patent applications |
Patent application number | Title | Published |
20120328677 | Active Agent Formulations, Methods of Making, and Methods of Use - An active agent composition includes particles containing a water-insoluble active agent or an active agent with a significant food effect; and a ternary amine polymer having both hydrophobic (meth)acrylate units and acid-soluble (meth)acrylate units, and an acidifying agent; wherein upon ingestion by a human subject, the acidifying agent facilitates the dissolution of the ternary amine polymer in the gastrointestinal tract. | 12-27-2012 |
20120065992 | SYSTEM AND METHODS FOR PHARMACY MANAGEMENT OF DRUGS - Described herein is a computer program product for pharmacy management and its application for using drugs that are P-glycoprotein or CYP3A4 inhibitors. Also included is a method of using a first drug in a patient receiving a prescription for the first drug. The computer program performs a method including issuing a drug-drug interaction alert when a patient is receiving a first drug and a concomitantly administered second drug. | 03-15-2012 |
20120065991 | SYSTEM AND METHODS FOR PHARMACY MANAGEMENT OF DRUGS - Described herein is a computer program product for pharmacy management and its application for using drugs that are P-glycoprotein or CYP3A4 inhibitors. Also included is a method of using a first drug in a patient receiving a prescription for the first drug. The computer program performs a method including issuing a drug-drug interaction alert when a patient is receiving a first drug and a concomitantly administered second drug. | 03-15-2012 |
20120046262 | MEGESTROL ACETATE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE - Disclosed herein is a method of using megestrol acetate. In one embodiment, the method comprises informing a user that megestrol acetate is metabolized by a cytochrome p450 isozyme. In another embodiment, the method comprises obtaining megestrol acetate from a container associated with published material providing information is metabolized by a cytochrome p450 siozyme. Also disclosed are articles of manufacture comprising a container containing a dosage form of megestrol acetate, wherein the container is associated with published material informing that megestrol acetate is metabolized by a cytochrome p450 siozyme, a method of treatment, and a method of manufacturing a megestrol acetate product. | 02-23-2012 |
20110263716 | COLCHINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 10-27-2011 |
20110229437 | Method of Treating Asthma with Antiviral Agents - The present invention provides a method of treating asthma by administering a therapeutically effective amount of an antiviral agent to a patient. The antiviral agent may be a neuraminidase inhibitor, a viral fusion inhibitor, a protease inhibitor, a DNA polymerase inhibitor, a signal transduction inhibitor, a nucleoside reverse transcriptase inhibitor (NRTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an interferon. The antiviral agent may be administered to the patient by inhalation, nasally, intravenously, orally, subcutaneously, intramuscularly or transdermally. For example, the antiviral agent may be formulated for delivery as aerosols to the patient. | 09-22-2011 |
20110213037 | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | 09-01-2011 |
20110207825 | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | 08-25-2011 |
20110190397 | Methods for Concomitant Administration of Colchicine and a Second Active Agent - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 08-04-2011 |
20110190396 | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | 08-04-2011 |
20110124694 | BIOAVAILABLE COMPOSITIONS OF METAXALONE AND PROCESSES FOR PRODUCING THE SAME - Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin® tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin® 400-mg tablets after oral administration to fasting human subjects. | 05-26-2011 |
20110065721 | METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE - Disclosed herein are methods of using metaxalone. In one embodiment, the method comprises determining that a patient in need metaxalone therapy is taking a substance that is a n inhibitor or an inducer of a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4, and adjusting administration to the patient of metaxalone or the substance to avoid an adverse event associated with metaxalone. In another embodiment, the method comprises informing a user that metaxalone is metabolized by a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product. | 03-17-2011 |
20110046228 | METHODS FOR ADMINISTRATION OF COLCHICINE WITH GRAPEFRUIT JUICE - Methods for safe administration of colchicine together with consumption of grapefruit juice are disclosed. | 02-24-2011 |
20110046227 | METHODS FOR CONCOMITANT ADMINISTRATION OF COLCHICINE AND A SECOND ACTIVE AGENT - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., atorvastatin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 02-24-2011 |
20110039940 | Methods for Concomitant Administration of Colchicine and a Second Active Agent - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 02-17-2011 |
20100305172 | Methods for Concomitant Administration of Colchicine and a Second Active Agent - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 12-02-2010 |
20100305171 | Methods for Concomitant Administration of Colchicine and a Second Active Agent - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 12-02-2010 |
20100222290 | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | 09-02-2010 |
20100179169 | Methods for Concomitant Administration of Colchicine and a Second Active Agent - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 07-15-2010 |
20100159010 | Active Agent Formulations, Methods of Making, and Methods of Use - An active agent composition includes particles containing a water-insoluble active agent or an active agent with a significant food effect; and a ternary amine polymer having both hydrophobic (meth)acrylate units and acid-soluble (meth)acrylate units, and an acidifying agent; wherein upon ingestion by a human subject, the acidifying agent facilitates the dissolution of the ternary amine polymer in the gastrointestinal tract. | 06-24-2010 |
20100137235 | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | 06-03-2010 |
20100105780 | COLCHICINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 04-29-2010 |
20090318561 | COLCHICINE PRODUCTS, METHOD OF MANUFACTURE, AND METHODS OF USE - Disclosed herein is a method of using colchicine. In one embodiment, the method comprises administering to a patient colchicine and a substrate of cytochrome P450 1A2 and monitoring the patient during administration of colchicine and the substrate for an adverse event. Also disclosed are articles of manufacture comprising a container containing a dosage form of colchicine and a method of manufacturing a colchicine product. | 12-24-2009 |
20090298948 | COLCHICINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 12-03-2009 |
20090221700 | Carisprodol Articles and Methods - A method of using carisoprodol comprises informing a user that administration of carisoprodol in the presence of food decreases the C | 09-03-2009 |
20090215904 | COLCHICINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 08-27-2009 |
20090170952 | COLCHICINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 07-02-2009 |
20090118237 | Carisoprodol, Phenytoin and Fosphenytoin Articles and Methods - A method of using carisoprodol, phenytoin or fosphenytoin comprises informing a user that co-administration of carisoprodol with phenytoin or fosphenytoin results in an increase in free phenytoin blood levels, a decrease in total phenytoin levels, or both. In another embodiment, a method of using carisoprodol, phenytoin or fosphenytoin comprises informing a user that when co-administering carisoprodol with phenytoin or fosphenytoin, the level of free phenytoin in a patient serum should be monitored, the level of total phenytoin should be monitored, or both. Also included are methods and articles of manufacture. | 05-07-2009 |
20090093548 | COLCHINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 04-09-2009 |
20090074872 | Active Agent Formulations, Methods of Making, and Methods of Use - Stable fenofibrate suspensions are disclosed herein. A fenofibrate composition includes fenofibrate nanoparticles having an average particle size of less than 500 nm, and a particle sequestrant, wherein the average particle size of the nanoparticulate suspension changes by less than 50% after standing at room temperature for 21 or more days. | 03-19-2009 |
20090036414 | Mesalamine Formulations - Disclosed are oral dosage forms comprising an effective amount of mesalamine, wherein the dosage form has a dissolution profile such that greater than 5 wt % of the total weight of the mesalamine in the dosage form is released during a pH 6.0 portion of a dissolution test, the dissolution test comprising stirring in a pH 6.0 solution for 1 hour, followed by stirring in a pH 7.2 solution for an additional hour. In some embodiments, the dosage form releases less than all of the mesalamine to the right side of the colon. Release of less than all of the mesalamine dosage form to the right side of the colon may be determined by the in vitro dissolution profile of the dosage form. | 02-05-2009 |
20080292584 | METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE - Disclosed herein are methods of using metaxalone. In one embodiment, the method comprises determining that a patient in need metaxalone therapy is taking a substance that is a n inhibitor or an inducer of a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4, and adjusting administration to the patient of metaxalone or the substance to avoid an adverse event associated with metaxalone. In another embodiment, the method comprises informing a user that metaxalone ais metabolized by a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product. | 11-27-2008 |
20080234341 | Carisoprodol and Phenytoin Methods - A method of using carisoprodol comprises informing a user that co-administration of carisoprodol with steady-state phenyloin results in an increase in free phenyloin blood levels, a decrease in total phenyloin blood levels, or both. In another embodiment, a method of using carisoprodol comprises informing a user that when co-administering carisoprodol with steady-state phenyloin, the level of free phenyloin in a patient serum should be monitored, the level of total phenyloin should be monitored, or both. Also included are methods and articles of manufacture. | 09-25-2008 |
20080221156 | STABLE FORMULATIONS OF ACE INHIBITORS, AND METHODS FOR PREPARATION THEREOF - The present invention provides stable formulations of ACE inhibitors, especially enalapril maleate, that can be manufactured in a time efficient, cost effective manner. Such formulations can be prepared simply and on a large industrial scale. The present invention also provides methods for the preparation of stable formulations of ACE inhibitors, especially enalapril maleate. | 09-11-2008 |
20080220076 | Active Agent Formulations, Methods of Making, and Methods of Use - Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof, are also disclosed. | 09-11-2008 |